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Objective:  To  estimate  the  prevalence  of  hepatitis  B virus  (HBV)  infection  and  vaccine-induced  immunity
in the  region  of Madrid,  and  to analyze  their  evolution  over  time.
Methods:  An observational,  analytical,  cross-sectional  study  was  carried  out  in the population  aged  16–
80 years  between  2008  and  2009.  This  was  the  last  of  four  seroprevalence  surveys  in  the region  of  Madrid.
The prevalence  of  HBV  infection  and  vaccine-induced  immunity  was  estimated  using  multivariate  logistic
models  and  were  compared  with  the  prevalences  in  the  1989,  1993  and  1999  surveys.
Results:  In the  population  aged  16–80  years,  the  prevalence  of  HBV  infection  was  11.0% (95%  CI:  9.8–12.3)
and  that  of  chronic  infection  was 0.7%  (95%  CI: 0.5–1.1).  The  prevalence  of  vaccine-induced  immunity  in
the  population  aged  16–20  years  was  73.0%  (95%  CI: 70.0–76.0).  Compared  with  previous  surveys,  there
was  a decrease  in  the  prevalence  of HBV  infection.
Conclusions:  Based  on  the  prevalence  of  chronic  infection  (<1%),  Madrid  is a region  with  low  HBV  ende-
micity.  Preventive  strategies  against  HBV  should  especially  target  the  immigrant  population.
©  2013  Published  by  Elsevier  España,  S.L.U.  on  behalf  of  SESPAS.
Infección  por  el  virus  de  la  hepatitis  B  e  inmunidad  inducida  por  la  vacuna
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Objetivo:  Estimar  la  prevalencia  de  infección  por  hepatitis  B(HB)  e inmunidad  vacunal  en  la  Comunidad
de  Madrid  y analizar  su evolución  en  el tiempo.
Métodos:  Estudio  observacional  analítico  transversal  en  población  de  16-80  an˜os,  en  2008-2009.  Ésta  es
la  última  de  cuatro  encuestas  de  seroprevalencia.  La prevalencia  de infección  por  HB  e  inmunidad  vacunal
fue  estimada  usando  modelos  logísticos  multivariantes  y  se compararon  con  las encuestas  de  1989,  1993
y  1999.
Resultados:  En  población  de 16-80  an˜os,  la  prevalencia  de  infección  por  HB  fue  11,0%  (IC-95%:9,8-12,3)
y  0,7%  (IC-95%:0,5-1,1)  de  infección  crónica.  La  prevalencia  de inmunidad  vacunal  en población  de  16-
20  an˜os  fue 73,0%  (IC-95%:70,0-76,0).  En  comparación  con  anteriores  encuestas  la  prevalencia  de  infección
disminuyó.
Conclusiones:  Madrid  es una  región  de  baja  endemicidad  de  HB,  de  acuerdo  a  la  prevalencia  de  infec-
ción  crónica  (<1%).  Las  estrategias  de  prevención  de  la  HB  deben  dirigirse  especialmente  a la  población
inmigrante.
©  2013  Publicado  por  Elsevier  España,  S.L.U.  en  nombre  de  SESPAS.ntroductionEurope is a low to intermediate endemicity region for Hep-
titis B (HB).1 The Spanish Seroprevalence Survey, carried out in
∗ Corresponding author.
E-mail address: luis.garcia@salud.madrid.org (L. García-Comas).
http://dx.doi.org/10.1016/j.gaceta.2014.05.007
213-9111/© 2013 Published by Elsevier España, S.L.U. on behalf of SESPAS.1996, reported prevalence rates for HB virus exposure and chronic
infection of 4.5% and 0.8%, respectively, for the population aged 2–
39 years.2
The Region of Madrid began vaccinating risk groups in the 1980s.
In 1994 the HB vaccine was  included in the vaccination schedule for
infants (0–1–6 months). In 1996, a mixed vaccination programme
was established that included vaccination at 11 years of age (dis-
continued in 2005) and vaccination for infants.
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Table  1
Prevalence of HB Infection and possible risk factors. Fourth Seroprevalence Survey of the region of Madrid, 2008–2009.
Factor N Prevalence (95% CI) OR unadjusted (95% CI) OR adjusteda (95% CI)
HB infection Chronic HB infection HB infection Chronic HB infection HB infection Chronic HB infection
Sex
Female 1967 9.5 (8.1–11.2) 0.5 (0.2–1.1) 1.0 1.0 1.0 1.0
Male  1719 12.6 (10.9–14.6) 0.9 (0.5–1.5) 1.4 (1.1–1.7) 1.8 (0.7–4.6) 1.5 (1.1–2.0) 1.8 (0.7–4.7)
Origin
Spain  2745 10.4 (9.1–11.9) 0.6 (0.4–1.1) 1.0 1.0 1.0 1.0
Abroad 941 13.9 (11.4–16.9) 1.1 (0.5–2.1) 1.4 (1.1–1.8) 1.7 (0.7–4.0) 2.3 (1.6–3.2) 2.1 (0.9–5.0)
Age
16–20  y 740 1.3 (0.7–2.6) 0.2 (0.0–0.8) 1.0 1.0 1.0 1.0
21–30 y 830 4.6 (3.3–6.4) 0.5 (0.2–1.3) 3.6 (1.6–8.0) 2.5 (0.5–13.1) 4.0 (1.8–9.0) 2.3 (0.4–11.7)
31–40  y 766 7.2 (5.7–9.0) 0.6 (0.2–1.5) 5.7 (2.7–11.9) 3.0 (0.5–17.9) 6.7 (3.2–13.9) 2.9 (0.5–17.2)
41–60  y 742 12.2 (10.3–14.3) 1.1 (0.5–2.1) 10.2 (5.1–20.2) 5.7 (1.1–29.1) 13.8 (6.7–28.3) 5.9 (1.2–30.1)
61–80  y 608 22.8 (19.6–26.3) 0.7 (0.3–1.8) 21.7 (10.9–43.3) 3.6 (0.6–21.0) 28.3 (13.6–58.9) 4.1 (0.7–24.2)
Education
Below  primary 578 20.1 (17.0–23.6) 0.9 (0.4–2.0) 1.0 1.0 1.0 1.0
Primary 1204 11.6 (9.5–14.1) 0.5 (0.2–1.3) 0.5 (0.4–0.7) 0.6 (0.2–2.0) 0.8 (0.6–1.2) 0.7 (0.2–2.7)
Secondary 1025 9.0 (7.3–11.1) 0.7 (0.3–1.8) 0.4 (0.3–0.5) 0.8 (0.2–2.9) 0.7 (0.5–1.0) 1.0 (0.2–4.6)
University 832 6.2 (4.6–8.5) 0.8 (0.4–2.0) 0.3 (0.2–0.4) 1.0 (0.3–3.3) 0.5 (0.3–0.9) 1.2 (0.3–5.3)
No  data 47
Socioeconomic class
I–II 891 7.1 (5.3–9.4) 0.3 (0.1–1.1) 1.0 1.0 1.0 1.0
III  874 10.5 (8.7–12.7) 0.7 (0.3–2.0) 1.5 (1.1–2.2) 2.2 (0.5–10.5) 1.4 (1.0–2.0) 2.2 (0.5–10.3)
IVa  938 14.1 (11.9–16.5) 1.0 (0.4–2.1) 2.2 (1.5–3.1) 2.8 (0.7–12.2) 1.5 (1.0–2.3) 2.6 (0.6–11.8)
IVb–V  886 12.8 (10.2–15.8) 0.7 (0.3–1.6) 1.9 (1.3–2.8) 2.1 (0.5–9.5) 1.5 (1.0–2.3) 1.8 (0.4–8.9)
No  data 97
Exposure to blood-borne transmission risk
No 2458 11.0 (9.6–12.6) 0.8 (0.5–1.3) 1.0 1.0 1.0 1.0
Yes  1228 11.1 (9.3–13.3) 0.5 (0.2–1.4) 1.0 (0.8–1.3) 0.7 (0.2–2.1) 1.2 (0.9–1.6) 0.8 (0.3–2.3)
Cohabitation with person(s) with hepatitis
No 3301 11.2 (10.0–12.6) 0.6 (0.4–1.0) 1.0 1.0 1.0 1.0
Yes  303 9.2 (6.1–13.6) 1.0 (0.3–3.8) 0.8 (0.5–1.3) 1.7 (0.4–7.5) 1.0 (0.6–1.6) 1.9 (0.4–8.3)
No  data 82
Consultation for a liver problem
No 3598 11.0 (9.9–12.3) 0.7 (0.4–1.1) 1.0 1.0 1.0 1.0
Yes  88 12.5 (5.4–26.3) 1.6 (0.3–8.2) 1.2 (0.5–2.9) 2.3 (0.4–14.3) 1.3 (0.5–3.8) 2.7 (0.4–16.4)
a HB infection OR is adjusted by sex, age, origin, education and socioeconomic class; and Chronic HB infection OR is adjusted by sex and age.
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HIn the region of Madrid, seroprevalence surveys are conducted as
art of the Epidemiological Surveillance Network3 since 1988. The
im of our study was to estimate the prevalence of HB infection and
accine-induced immunity in the region of Madrid, and to analyze
ts evolution over time.
ethods
This is an observational, analytical, cross-sectional study on the
esidents or the region of Madrid aged 16–80 years that attended
lood extraction centres between January and June 2008 and
etween October and December 2009. The sampling plan was  bi-
tage, cluster (by socioeconomic class) and stratiﬁed (by proportion
f immigrants) design, which resulted in the selection of 78 basic
reas of health that represents the 247 of Region of Madrid. Immi-
rant population was sample at a higher frequency than the rest to
rovide more precise estimates in this group. Similar sampling has
een used in other seroprevalence surveys.4
Patients with diseases or conditions that could interfere with
he immune response were excluded. Socio-demographic factors,
istory of hepatitis, vaccination status and exposure to bloodborne
isk were collected by trained interviewers. Eligible individuals
ave informed consent to be part of this study, and the study was
pproved by the ethical committee of the Ramón y Cajal University
ospital.HB proﬁles analyzed were as follows: past resolved
infection (positive anti-HBc and positive anti-HBs); chronic
HB infection (positive anti-HBc, negative anti-HBs and positive
HBsAg); isolated infection (only positive anti-HBc) and ﬁnally,
vaccine-induced immunity (positive anti-HBs and negative
anti-HBc).
Anti-HBc antibodies were detected by competitive enzyme-
linked immunosorbent assay (ELISA) (sensitivity: 99.0%, speciﬁcity
between 99.6% and 99.7%) and anti-HBs antibodies were detected
using one-step sandwich ELISA (Enzygnost® Siemens-GmbH, Ger-
many) (sensitivity: 99.1%, speciﬁcity: 99.8%). Anti-HBc positive
and anti-HBs negative samples were then processed to detect
HBsAg using two-step ELISA (Enzygnost® Siemens-GmbH, Ger-
many) (sensitivity: 100%, speciﬁcity: 99.8%) and HBsAg positivity
was conﬁrmed by repeating the test.
Prevalence for the four immune proﬁles was  estimated over-
all and according to sociodemographic characteristics. Possible risk
factors for HB infection (positive anti-HBc) and chronic HB infection
such as age, sex, country of origin, education level and socioecono-
mic  class were analyzed using univariate and multivariate logistic
regression models. Prevalence estimations and regressions models
were weighted to account for oversampling immigrant population.
Prevalence data from previous surveys (1988, 1993 and 1999)
were used to study the HB infection evolution over time. The
sampling method used in past surveys was  the same as the one
494 A.M. Pedraza-Flechas et al. / Gac Sanit. 2014;28(6):492–495
19
88
19
93
19
99
20
08
19
88
19
93
19
99
20
08
0 10 20 30 40 0 10 20 30 40
16-20 years 21-30 years
31-40 yearsa 41-60 yearsb
Y
ea
r
Prevalence (%) 
Figure 1. Trend of the HB infection prevalence by age, 1988–2008. Madrid, Spain.
a Information for the ﬁrst Madrid prevalence survey (1988) corresponds to the age group 21–40 years.
b Information for the ﬁrst Madrid prevalence survey (1988) corresponds to the age group 55 years or older.
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Tsed in the present one.5,6 A multivariate logistic regression model
djusted for sex and age was used to compare prevalence in this
urvey with that in the 1999 survey.
esults
A total of 3695 subjects participated in the study, for a response
ate of 69.4%. The response rate was higher among women  (73.0%),
nd among 40 years old or younger subjects (72.6%). In 9 cases,
lood samples were not suitable.
Prevalence of HB infection in the population aged 16–80 years
as 11.0% (95% conﬁdence interval (CI): 9.8–12.3). Immigrants with
B infection were from Latin America (41.1%), Africa (29.2%), East-
rn Europe (22.3%), Southeast Asia (5.6%), the Middle East (1.3%)
nd Western Europe (0.6%).
Of the subjects with HB infection, 80.0% (95% CI: 74.9–84.3) had
ast resolved infection (anti-HBc positive and anti-HBs positive),
.3% (95% CI: 4.1–9.4) were chronically infected, and 13.7% (95% CI:
0.1–18.4) had isolated anti-HBc.
Chronic HB prevalence in the population aged 16–80 years was
.7% (95% CI: 0.5–1.1). The proportion of carriers who reported a
istory of HBV was 46.4% (95% CI: 24.4–70.0). Prevalence and OR
y socio-demographic factors are presented in Table 1.
Fig. 1 shows the HB prevalence for all the seroprevalence sur-
eys. A decreasing trend in prevalence of HB infection in 2008
ompared with 1999 is observed (OR: 0.7; 95% CI: 0.5–0.9), espe-
ially in population between 41 and 60 years of age (OR: 0.6; 95%
I: 0.4–0.8). No signiﬁcant differences were detected in relation
o previous surveys, although estimated prevalence rates for the
roups aged 16–20 years and 21–30 years were lower than that in
he 1999 survey.
The prevalence of vaccine-induced immunity to HBV in the pop-
lation aged 16–80 years was 26.3% (95% CI: 24.7–28.0). Prevalence
or the group aged 16–20 years, consisting of cohorts recommended
or vaccination at 11 years of age, was 73.0% (95% CI: 70.0–76.0).
his ﬁgure was signiﬁcantly lower for the immigrant populationcompared to the Spanish-born population (OR: 0.2; 95% CI: 0.2–0.4)
and for men  compared to women (OR: 0.6; 95% CI: 0.4–0.8).
Discussion
HB prevalence in the population aged 16–80 years in the region
of Madrid is 11.0%. Prevalence has decreased compared to previ-
ous surveys, possibly due to the effectiveness of control measures
for at-risk groups (safe sex practices, use of individual syringes,
vaccination).
In this study, seroprevalence of infection is 2.5 times higher
in people coming from immigrant than in native population.
These data are consistent with the ones reported in other areas
of the region.1,6 It is advisable to consider targeting disease
prevention programmes in immigrant populations coming from
high-endemicity regions as a cost effective measure.1,7,8
Chronic HB infection prevalence in the region of Madrid is low
(<2%) and is below both the 1996 rate reported for Spain overall and
the rates reported for other regions of Spain.2,9–12 Since chronic HB
infection prevalence remains below 1% even considering that the
population aged under 16 years is excluded from the analysis, Spain
can be classiﬁed as a low-endemicity country.
Immunization is another factor inﬂuencing the HB prevalence
proﬁle for the region of Madrid. HB vaccination at 11 years of age
was introduced in 1996 with a coverage of vaccination at ranged
from 59.7% to 68.8%.13 However, this coverage ﬁgure is probably
underestimated, given that vaccine-induced immunity prevalence
for this group is 73.0% and due to loss of the ability to detect antibod-
ies identiﬁed in individuals who retain good immune response.14
Signiﬁcant reductions in infection can be expected in the coming
years as the routine immunization target cohorts reach the age of
highest transmission risk.
Although the main reason for non-participation in the study
was lack of interest or time (78%), a healthy volunteer bias may
be underestimating the prevalence of the disease.
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[cited 2011 August 4].
14. Chaves SS, Fischer G, Groeger J, et al. Persistence of long-term immunity
to hepatitis B among adolescents immunized at birth. Vaccine. 2012;30:
1644–9.A.M. Pedraza-Flechas et al. 
The lower vaccine-induced immunity and higher prevalence of
nfection in the immigrant population make a priority to focus the
B preventive strategies to these high risk groups.
What is known about this issue?
According to the last Spanish Seroprevalence Survey, the
prevalence for Hepatitis B exposure and chronic infection was
4.5% and 0.8%, respectively.
What does this study add to the literature?
In the Region of Madrid, Hepatitis B prevalence has shown
a decreasing trend in the last 20 years and vaccine-induced
immunity is lower in the immigrant population.
Implication for health
policy/practice/research/medical education:
In order to reduce the prevalence of Hepatitis B in the
Region of Madrid, understanding of risk factors associated is
mandatory.
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